IP Library › Granted Patent US 11,466,097
Granted Patent B2
US 11,466,097 · App. 15/766,674 · Granted Oct 11, 2022

Chimeric antigen receptors targeted to PSCA

Inventors: Saul J. Priceman (Duarte, CA); Christine E. Brown (Duarte, CA); Stephen J. Forman (Duarte, CA)
Assignee: City of Hope
C07K16/3069A61K35/17A61K48/00A61P1/18A61P19/08A61P35/00A61P35/04C07H21/00C07H21/04C07K14/7051C07K14/70514C07K14/70517C07K14/70521C12N5/00C12N5/06C12N5/0602C12N5/0634C12N5/0636C12N5/10C12N15/00C12N15/09C12N15/10C12N15/11C12N15/62C12N15/63C12N15/70C12N15/74C12N15/79C12N15/85C07H19/00C07H19/06C07H19/16C07K2317/24C07K2317/53C07K2317/622C07K2317/73C07K2317/76C07K2319/02C07K2319/03C07K2319/33C12N15/8509C12N2015/8518C12N2015/8572
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,466,097
App. No.
15/766,674
Granted
Oct 11, 2022
Kind
B2
Abstract

Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.

Claims (13)

1. A nucleic acid molecule encoding a chimeric antigen receptor comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 28, 30, 32, 34 and 36.

2. A population of human T cells comprising a nucleic acid encoding a chimeric antigen receptor comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 28, 30, 32, 34 and 36.

3. The population of human T cells of claim 2 , wherein the population of T cells comprises central memory T cells.

4. A chimeric antigen receptor comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 28, 30, 32, 34 and 36.

5. The nucleic acid molecule of claim 1 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 and 32.

6. The nucleic acid molecule of claim 1 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 28 and 34.

7. The nucleic acid molecule of claim 1 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30 and 36.

8. The population of human T cells of claim 2 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 and 32.

9. The population of human T cells of claim 2 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 28 and 34.

10. The population of human T cells of claim 2 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30 and 36.

11. The chimeric antigen receptor of claim 4 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 and 32.

12. The chimeric antigen receptor of claim 4 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 28 and 34.

13. The chimeric antigen receptor of claim 4 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30 and 36.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2019
From: PRICEMAN, SAUL J.; BROWN, CHRISTINE E.; FORMAN, STEPHEN J.
To: CITY OF HOPE
Reel/Frame 048193/0465 →
Continuity (2)
Provisional Application 62238062 · Oct 6, 2015
Related Publication 20200308300A1 · Oct 1, 2020
Cited By (1)
US 12,565,535